- Home
- TRU vs IONS Comparison
TRU vs IONS Comparison
Compare TRU & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | IONS |
|---|---|---|
| Founded | 1968 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.1B |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TRU | IONS |
|---|---|---|
| Price | $65.43 | $45.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 24 |
| Target Price | ★ $92.24 | $83.64 |
| AVG Volume (30 Days) | 2.2M | ★ 3.7M |
| Earning Date | 10-27-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | ★ 60.00 | 21.71 |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $4,576,300,000.00 | N/A |
| Revenue This Year | $12.88 | N/A |
| Revenue Next Year | $7.72 | $48.41 |
| P/E Ratio | $31.66 | ★ N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $60.96 | $42.63 |
| 52 Week High | $89.12 | $86.74 |
Technical Indicators
Market Signals| Indicator | TRU | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 40.44 |
| Support Level | $63.90 | $43.01 |
| Resistance Level | $74.19 | $46.95 |
| Average True Range (ATR) | 2.43 | 1.69 |
| MACD | 0.08 | 0.43 |
| Stochastic Oscillator | 36.81 | 62.11 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).